WO2004064880A1 - Pansement d'hydrogel amorphe en cellulose microbienne - Google Patents

Pansement d'hydrogel amorphe en cellulose microbienne Download PDF

Info

Publication number
WO2004064880A1
WO2004064880A1 PCT/US2003/001162 US0301162W WO2004064880A1 WO 2004064880 A1 WO2004064880 A1 WO 2004064880A1 US 0301162 W US0301162 W US 0301162W WO 2004064880 A1 WO2004064880 A1 WO 2004064880A1
Authority
WO
WIPO (PCT)
Prior art keywords
dressing
cellulose
microbial
amorphous gel
wound
Prior art date
Application number
PCT/US2003/001162
Other languages
English (en)
Inventor
Gonzalo Serafica
Richard Mormino
Russel Hoon
Original Assignee
Xylos Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xylos Corporation filed Critical Xylos Corporation
Priority to JP2004566875A priority Critical patent/JP2006512981A/ja
Priority to PCT/US2003/001162 priority patent/WO2004064880A1/fr
Priority to AU2003303783A priority patent/AU2003303783A1/en
Priority to EP03007468A priority patent/EP1438975B1/fr
Priority to AT03007468T priority patent/ATE309825T1/de
Priority to DE60302326T priority patent/DE60302326T2/de
Publication of WO2004064880A1 publication Critical patent/WO2004064880A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives

Definitions

  • the invention relates to a wound dressing comprising microbial-derived cellulose in an amorphous hydrogel form.
  • wound dressings that demonstrate effectiveness to aid in the healing of wounds.
  • the components of these include various polymeric systems, cellulosic materials derived from plants and bacteria, and collagen. Each has its mode of action to assist the wound healing process. Many rely on either the donation of fluid to hydrate a wound surface and aid in removal of necrotic tissue through autolytic debridement or the absorption of excess fluid termed exudate.
  • Microbial-derived cellulose dressings are composed of bacterial cellulose and water. The processing of which, results in a dressing that possesses unique characteristics. Not only can it donate moisture which is associated with the dressing but its multi-layered three-dimensional structure, that distinguishes it from plant- derived cellulose, creates a material with a water-holding capacity up to 700 times its own dry weight, as described in U.S Patent 4,942,128. Microbial cellulose also demonstrates excellent wet tensile and compression strength. Lastly, by adjusting the cellulose to liquid ratio in processed microbial cellulose, the amount and rate of both fluid donation and absorption can be manipulated.
  • these patents illustrate a highly hydrated pad (80 to 1 fluid to cellulose ratio) that is able to provide a cooling capability ideal for burn applications.
  • the '146 patent describes the use of such liquid loaded pads as wet dressings for use as an ulcer dressing capable of providing moisture to the wound over an extended period of time.
  • the wet dressings described in the examples have the additional ability to absorb large quantities of fluid from the wound site when the dressing is applied in a less than saturated condition.
  • the wound dressings of Ring et al. fail to mention a singular dressing having both the ability to be a source of moisture for wounds as well as the ability to absorb fluid.
  • the Ring et al. patents also fail to describe the effective liquid to cellulose ratio to fabricate a dressing having the dual fluid handing capability.
  • the Ring et al. patents do not describe microbial-derived cellulose wound dressings in an amorphous gel form.
  • Amorphous hydrogel dressings for example IntraSite Gel (Smith & Nephew) differ from other dressings in their ability to add moisture to a dry wound and as such have been shown to be useful for debridmg necrotic dry tissue found in chronic and burn wounds. Since these hydrogels have not been cross-linked and therefore do not take a fixed shape, they have been termed amorphous (Ovington, L. G., Amorphous Gels Can Help Dry Escharic Wounds, Wound Care Institute Newsletter, July/ August 1997, Volume 2, No. 3).
  • the present inventors have developed a flowable cellulose-based gel wound dressing that possesses this novel fluid handling capability of absorption and donation.
  • production of a microbial-derived cellulose wound dressing in an amorphous gel form enhances the moisture donating aspect of the wound dressing relative to the unprocessed microbial cellulose starting film material.
  • This fluid handling capability is an end result of the processed microbial cellulose that contains the proper cellulose content for the intended purpose.
  • the resulting wound dressing can donate fluid if the wound surface is dry and found to be particularly useful for dry wounds covered with dry necrotic tissue or eschar. Here it acts to autolytically debride the wound: the necessary first step in healing of a chronic wound.
  • the same dressing is also capable of absorbing fluid away from the exuding wound bed.
  • chronic wounds such as venous ulcers tend to exude large amounts of fluids during the healing process.
  • the dressing of the present invention is able to absorb the fluid exudate while maintaining a moist surface for epithelial cells to migrate. The epithelial migration is essential for eventually closing the wound.
  • the flowable nature of this material allows this dressing to fill areas that a pad cannot effectively treat.
  • the amorphous gel dressing can be delivered to the entire wound bed surface.
  • the intimate contact of the gel dressing with the entire wound surface further enhances the moisture donation and absorption quality of microbial-derived cellulose and thereby improves wound healing.
  • the amorphous gel dressing can be easily removed without upsetting the newly forming tissue. Also, since it can be removed en bloc, the wound cleansing process, required for other gel dressing products, is greatly simplified.
  • the microbial-derived cellulose is biocompatible and nonpyrogenic.
  • an object of the present invention to provide an effective wound dressing comprising microbial cellulose that can flow to fill an area and then be easily removed when changing is necessary.
  • the preferred biosynthesized cellulose for the amorphous gel is produced by cellulose-producing organisms, such as Acetobacter xylinum, and is subjected to a series of chemical wash steps to render it non-pyrogenic. Once grown the typical processing uses hydroxide solutions at concentrations of 0.5-20% by weight. Preferably, sodium hydroxide is used at a concentration of not less than 1% by weight and most preferably about 2% to about 4% by weight in order to dissolve the cells. In addition, the present invention provides hydrogen peroxide washing capable of whitening and sanitizing the non-pyrogenic films.
  • Cellulose pellicles are typically composed of greater than 98% water and from 0.2 to 2% cellulose by weight. Subsequent to chemical processing, the pellicles are wet milled to produce the amorphous gel form with a cellulose content roughly equivalent to that of the starting material but which can be adjusted to any desired concentration through the addition or removal of fluids.
  • the amorphous gel wound dressing obtained from the milling and grinding of the intact microbial cellulose pellicles has a primary structure of ultra fine fibers that are known to be about 200 times finer than cotton fibers.
  • the secondary structure which is a non-woven pattern of interpenetrating cellulose fibers, is also not completely disrupted.
  • Typical cellulose content of the present invention ranges from about 1.0% to about 99% cellulose by weight, preferably about 2.5% to 65% by weight, more preferably about 3.0% to 50% by weight and most preferably 3.5 % to about 12% by weight. In an especially preferred embodiment, the cellulose content is about 4% or about 7% by weight.
  • the amorphous gel dressings of the invention can be used for donation of liquid to wounds as well as absorbing liquid from wounds.
  • the microbial- derived cellulose dressing can donate between about 40 to 85% of its liquid weight and can absorb between about 10 to 50%, more preferably the dressing can donate about 50 to 65% of its liquid weight and absorb about 15 to 35 % of its weight in liquid.
  • the flowable nature of the wound dressing can be manipulated by the addition of an ingredient for flow modification.
  • ingredients include but are not limited to polyols.
  • the polyols include propylene glycol, glycerol, polyethylene glycol and sorbitol and the like.
  • the rheological properties of the gel are easily adjusted by addition of liquids or solids such as polyols, i.e., polyethylene glycol, sorbitol, mannitol, glycerol, and propylene glycol or other flow modification agents such as lecithin and aloe vera.
  • concentration of these additives in the microbial cellulose gel may vary from 1% to 50%) by weight depending on the properties of the specific additive and on the desired flow characteristics of the resulting gel.
  • Liquid materials which can be loaded into the gel include but are not limited to water, isotonic saline, synthetic polymers such as polyethylene oxide, polyvinylpyrrolidone, aqueous solutions of molecules including proteins, such as platelet derived growth factor (PDGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), Transforming growth factor - beta (TGF- ⁇ ), bone morphogenetic protein (BMP), vascular endothelial growth factor (NEGF), nerve growth factor ( ⁇ GF), tumor angiogenesis factor (TAF), corticotropin releasing factor (CRF), interleukin-8 (IL-8), granulocyte-macrophage colony stimulating factor (GM-CSF), and other growth factors, and enzymes such as collagenase, papain and fibrinolysin desoxynuclease.
  • PDGF platelet derived growth factor
  • EGF epidermal growth factor
  • FGF fibroblast growth factor
  • IGF
  • the dressing may contain one or more active agents like antibiotics, such as bacitracin, polymyxin B, gentamicin, chloramphenicol, mupirocin, neomycin, silver sulfadiazine, gramicidin, and the like: topical anesthetics, such as lidocaine hydrochloride, benzocaine, dibucaine, tetracaine hydrochloride and the like: antifungal agents, such as clotrimazole, econazole, ketoconazole, miconazole, nystain, terbinafine, tolnaftate, undecylenic acid and the like; antiseptics and preservatives, such as polyhexamethylene biguanide, chlorhexidine digluconate, benzalkonium chloride, silver-based antimicrobials, copper-based antimicrobials and the like; antiviral agents, such as gentamycin sulfadiazine, dapsone, am
  • the amorphous gel form can be formulated to enhance the donation and/or absorption characteristics of the gel.
  • the content of microbial-derived cellulose present in the amorphous gel dressing can be manipulated depending upon the method of preparation and the eventual end use of the wound dressing.
  • the present invention also relates to a method of treatment of wounds using the inventive wound dressing, hi a preferred embodiment, chronic wounds or burns are treated with the inventive wound dressing.
  • the method comprises applying the wound dressing to the wound site, filling the wound with the hydrogel dressing, and covering the wound with a secondary film layer.
  • the frequency of changing the dressing is readily detennined by one skilled in the art. In one embodiment, the dressing is changed twice daily to weekly.
  • a microbial cellulose film is prepared.
  • the film is prepared by using microorganisms such as Acetobacter xylinum which are cultured in a bioreactor containing a liquid nutrient medium at 30 degrees °C at an initial pH of 3-6.
  • the medium is based on sucrose or other carbohydrates.
  • efficient film production is achieved using sucrose as a carbon source, ammonium salts as a nitrogen source, and corn steep liquor as nutrient source coupled with a proprietary trace elements supplement, which varies from the original Schramm & Hestrin medium (1954) used by those skilled in the art.
  • This proprietary trace elements supplement is quantified in the following table:
  • Suitable bioreactors are selected which minimize evaporation and provide adequate oxygen-limiting conditions.
  • Oxygen-limiting conditions may be varied depending upon the desired water content and thickness of the cellulose film. Generally, under oxygen-limited conditions, oxygen is present in an amount of 5%- 21%) of the total gas present at the air liquid interface.
  • the bioreactor is composed of plastic box fitted with an airtight cover or a limited gas-permeable cover. Dimensions of the bioreactor can vary in configuration (cube or cylinder) depending on the shape and size of the cellulose film being produced. For example, a six inch diameter cylinder will produce a six inch diameter dressing, which can be used as is or cut to conform to the wound to be treated, prior to application..
  • the Acetobacter utilizes the carbon available in the medium to produce more cellulose instead of using it for reproduction, thereby increasing the total yield of cellulose.
  • the fermentation process under static conditions was allowed to progress over for a period of about 7 - 30 days, during which the bacteria in the culture medium produced an intact cellulose pellicle containing the microorganisms.
  • the fermentation is stopped and the pellicle is removed from the bioreactor.
  • the excess medium contained in the pellicle is then removed by standard separation techniques such as compression or centrifugation prior to chemical cleaning and subsequent processing of the pellicle to yield a wound dressing with a cellulose to liquid ratio of about 1:10 to about 1:65.
  • the raw cellulose pellicle has an increased sugar:cellulose yield of about 35%), compared to literature values of 10%.
  • the cellulose pellicle is subjected to a series of chemical wash steps to convert the raw cellulose film into a medical grade and non-pyrogenic wound dressing material.
  • Typical processing uses hydroxide solutions at concentrations of 1-20% by weight.
  • sodium hydroxide is used at a concentration of not less than 3% and most preferably about 3% to about 5%> in order to dissolve the cells.
  • the present invention provides hydrogen peroxide washing capable of bleaching and sterilizing the pyrogen-free films. Concentrations of about 0.05% to about 10%> peroxide by weight are useful to effect whitening of the films.
  • the amount of peroxide used in about 0.1% to about 0.5%.
  • Other bleaching agents such as hypochlorite , hypobromite, and perborate may also be used.
  • the amount of cellular debris left in the cellulose pad after processing may be measured by Limulus Amebocyte Lysate (LAL) test as outlined by the U.S. Food and Drug Administration (FDA) in 21 CFR10.90.
  • LAL Limulus Amebocyte Lysate
  • FDA U.S. Food and Drug Administration
  • the instant cleaning process outlined above provided a nonpyrogenic cellulose pad ( ⁇ 0.05 EU/ml).
  • the allowable pyrogen content in Class I medical devices is 0.5 EU/ml (FDA LAL test Guideline).
  • the steps of the LAL test are defined by the test kit manufacturer and can simply be followed to yield the pyrogen level in the cellulose film.
  • This example presents a method for making an amorphous gel material from microbial cellulose sheets.
  • the cellulose sheets were processed using the method described in Example 1 to remove pyrogens and other contaminants, and compressed to obtain a cellulose content of approximately four percent.
  • a 500g quantity of the processed and depyrogenated microbial cellulose was placed in a 1 gal blender. To this 2500 ml of deionized water was added, and the mixture was processed using a 3 hp motor at high speed for 5 min to ensure consistency. The resulting mixture was decanted into a draining bin, and excess water was allowed to drain. After draining for 15 min, the mixture was pressed until the weight of the gel again reached 500 g.
  • Example 3 Modification of Flow Properties This example demonstrates how the viscosity and flow properties of a microbial cellulose amorphous gel can be modified through the addition of an ingredient for flow modification.
  • Amorphous gel was produced by the method described in example 1, and the final cellulose content was determined to be 3.95% by drying of 20g aliquots. Using this gel, nine 50g samples were prepared containing 0 to 40 percent propylene glycol by weight. The gels were mixed thoroughly to distribute the propylene glycol and then packed into identical 5cc disposable syringes with 1.5mm tip openings.
  • This example shows how the properties of a microbial cellulose amorphous gel can be changed through the addition of active agents.
  • the amorphous gel used for this example was produced using the method described in example 1.
  • the 500 g gel was divided in half. The first half was modified with the addition of polyhexamethylene biguanide (PHMB) in sufficient quantity to give a 0.25% concentration. The second half of the gel was kept unchanged. Both gels were sterilized by gamma irradiation at 30-35 kGy. The samples then underwent antimicrobial testing. 10 g samples of each gel were inoculated with 10 5 cultures of either Staphylococcus aureus or Esherichia coli and incubated at 30°C. Organism populations were measured at time zero and again after 24 hr, and the totals of the PHMB-treated gel were compared with the untreated control.
  • PHMB polyhexamethylene biguanide
  • the amorphous gel treated with 0.25% PHMB reduced the bacterial population of both species by 99.99%, whereas the untreated amorphous gel resulted in significantly less reduction.
  • This example demonstrates the method of producing a wound dressing comprised of microbial cellulose amorphous gel.
  • This dressing will have the ability to both donate moisture to or absorb moisture from a wound site, depending on the state of the wound.
  • Amorphous gel was produced following the method described in example 1. Using the 500 g gel as a base material and assuming the initial cellulose content to be 4%, eight samples were created ranging from 1 to 10 percent cellulose according to the following table:
  • Donation testing was performed by spreading a 5 g sample of gel evenly over a 2 in diameter circular area on a 3 in x 3 in piece of pre- weighed smooth leather. Samples were removed after 2 hr and the leather was reweighed to determine the quantity of moisture donated to the dry surface. Donation results were reported as a percentage of the initial weight of the sample, and are shown graphically in Figure 3. Donation decreased nearly linearly up to 6% cellulose by weight, and then decreased more slowly up to the 11% by weight.
  • a wound dressing can be devised to accommodate both absorption and donation.
  • the gel In order to have measurable absorption, the gel would need to possess a minimum of 4% cellulose, and the gel would need less than 6% cellulose to donate significantly. Therefore, a wound dressing gel should contain between 4 and 6 percent cellulose to optimize the natural fluid handling ability of the microbial cellulose matrix.

Landscapes

  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Cette invention concerne un pansement en cellulose microbienne se présentant sous la forme d'un hydrogel pouvant être utilisé pour traiter les plaies et brûlures chroniques.
PCT/US2003/001162 2003-01-16 2003-01-16 Pansement d'hydrogel amorphe en cellulose microbienne WO2004064880A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2004566875A JP2006512981A (ja) 2003-01-16 2003-01-16 微生物由来セルロース無定形ヒドロゲル創傷包帯
PCT/US2003/001162 WO2004064880A1 (fr) 2003-01-16 2003-01-16 Pansement d'hydrogel amorphe en cellulose microbienne
AU2003303783A AU2003303783A1 (en) 2003-01-16 2003-01-16 Microbial-derived cellulose amorphous hydrogel wound dressing
EP03007468A EP1438975B1 (fr) 2003-01-16 2003-04-04 Pansement à base d'un gel amorphé contenant un dérivé microbien de la cellulose
AT03007468T ATE309825T1 (de) 2003-01-16 2003-04-04 Wundauflage mit amorphem hydrogel auf basis mikrobiell veränderter cellulose
DE60302326T DE60302326T2 (de) 2003-01-16 2003-04-04 Wundauflage mit amorphem Hydrogel auf Basis mikrobiell veränderter Cellulose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/001162 WO2004064880A1 (fr) 2003-01-16 2003-01-16 Pansement d'hydrogel amorphe en cellulose microbienne

Publications (1)

Publication Number Publication Date
WO2004064880A1 true WO2004064880A1 (fr) 2004-08-05

Family

ID=32769582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/001162 WO2004064880A1 (fr) 2003-01-16 2003-01-16 Pansement d'hydrogel amorphe en cellulose microbienne

Country Status (3)

Country Link
JP (1) JP2006512981A (fr)
AU (1) AU2003303783A1 (fr)
WO (1) WO2004064880A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7832857B2 (en) 2008-08-18 2010-11-16 Levinson Dennis J Microbial cellulose contact lens
WO2011151835A1 (fr) * 2010-06-03 2011-12-08 Bharat Biotech International Limited Nouvelle composition pharmaceutique synergique pour applications topiques
US9970303B2 (en) 2014-05-13 2018-05-15 Entrotech, Inc. Erosion protection sleeve
CN115487340A (zh) * 2022-10-31 2022-12-20 振德医疗用品股份有限公司 一种负载活性氧的细菌纤维素敷料及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT509289B1 (de) * 2009-12-28 2014-06-15 Chemiefaser Lenzing Ag Funktionalisierter cellulosischer formkörper und verfahren zu seiner herstellung

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588400A (en) * 1982-12-16 1986-05-13 Johnson & Johnson Products, Inc. Liquid loaded pad for medical applications
US5558861A (en) * 1986-04-22 1996-09-24 Ajinomoto Co., Inc. Modified microbially-produced cellulose gel with human epidermal cells adsorbed thereon for use as a skin graft or vulnerary cover
US5662924A (en) * 1991-03-21 1997-09-02 Smith & Nephew Plc Wound dressing
US6071727A (en) * 1995-08-01 2000-06-06 Rensselaer Polytechnic Institute Production of microbial cellulose
US20020107223A1 (en) * 2000-11-21 2002-08-08 Oster Gerry Ann Solvent dehydrated microbially-derived cellulose for in vivo implantation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588400A (en) * 1982-12-16 1986-05-13 Johnson & Johnson Products, Inc. Liquid loaded pad for medical applications
US5558861A (en) * 1986-04-22 1996-09-24 Ajinomoto Co., Inc. Modified microbially-produced cellulose gel with human epidermal cells adsorbed thereon for use as a skin graft or vulnerary cover
US5662924A (en) * 1991-03-21 1997-09-02 Smith & Nephew Plc Wound dressing
US6071727A (en) * 1995-08-01 2000-06-06 Rensselaer Polytechnic Institute Production of microbial cellulose
US20020107223A1 (en) * 2000-11-21 2002-08-08 Oster Gerry Ann Solvent dehydrated microbially-derived cellulose for in vivo implantation

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7832857B2 (en) 2008-08-18 2010-11-16 Levinson Dennis J Microbial cellulose contact lens
WO2011151835A1 (fr) * 2010-06-03 2011-12-08 Bharat Biotech International Limited Nouvelle composition pharmaceutique synergique pour applications topiques
AU2010354681B2 (en) * 2010-06-03 2014-08-28 Bharat Biotech International Limited A novel synergistic pharmaceutical composition for topical applications
KR101457509B1 (ko) * 2010-06-03 2014-11-05 브하라트 바이오테크 인터내셔날 리미티드 국소 적용을 위한 신규의 상승적 약제학적 조성물
AU2010354681C1 (en) * 2010-06-03 2015-02-05 Bharat Biotech International Limited A novel synergistic pharmaceutical composition for topical applications
US9427459B2 (en) 2010-06-03 2016-08-30 Bharat Biotech International Limited Synergistic pharmaceutical composition for topical applications
US9970303B2 (en) 2014-05-13 2018-05-15 Entrotech, Inc. Erosion protection sleeve
CN115487340A (zh) * 2022-10-31 2022-12-20 振德医疗用品股份有限公司 一种负载活性氧的细菌纤维素敷料及其制备方法
CN115487340B (zh) * 2022-10-31 2023-11-17 振德医疗用品股份有限公司 一种负载活性氧的细菌纤维素敷料及其制备方法

Also Published As

Publication number Publication date
JP2006512981A (ja) 2006-04-20
AU2003303783A1 (en) 2004-08-13

Similar Documents

Publication Publication Date Title
US20040142019A1 (en) Microbial-derived cellulose amorphous hydrogel wound dressing
Portela et al. Bacterial cellulose: a versatile biopolymer for wound dressing applications
EP1473047B1 (fr) Pansement en cellulose microbielle sous forme de feuille, comprenant PHMB, pour plaies chroniques
CA2506638C (fr) Pansement a base de collagene et bioabsorbable
EP1356831B1 (fr) Pansement à base de cellulose microbienne pour le traitement de plaies chroniques
CA2271266C (fr) Matiere plastique spongieuse desinfectante
FI126109B (en) Nanofibril polysaccharide for use in the control and prevention of constriction and scarring
US20050019380A1 (en) Microbial cellulose wound dressing for treating chronic wounds
JPH04502569A (ja) 創傷治療用ゲル配合物
EP1438975B1 (fr) Pansement à base d'un gel amorphé contenant un dérivé microbien de la cellulose
Yang et al. A review on antimicrobial silver absorbent wound dressings applied to exuding wounds
CN110876815A (zh) 一种负载富血小板血浆和抗菌肽的水凝胶及其制备方法和应用
RU2437681C1 (ru) Раневое покрытие с лечебным действием
CN111068103B (zh) 一种手术伤口用长效抑菌凝胶敷料及其制备方法
CA2484953C (fr) Pansement de plaie a base de cellulose d'origine microbienne destine au traitement de plaies chroniques
WO2004064880A1 (fr) Pansement d'hydrogel amorphe en cellulose microbienne
KR102088475B1 (ko) Hr-키토산 드레싱의 제조방법 및 그에 의한 hr-키토산 드레싱
Voncina et al. Active textile dressings for wound healing
KR20050039960A (ko) 키토산을 이용한 폼 드레싱재 및 이의 제조방법
CN113045848A (zh) 一种聚乙烯醇纳米复合水凝胶的制备方法
Alibolandi et al. Biopolymer-Based Hydrogel Wound Dressing
CN109381733A (zh) 一种表面粗糙度可控的高岭土/海藻酸钙膜止血抗菌敷料的制备方法
Elsner et al. Novel composite antibiotic-eluting structures for wound healing applications
JPH08294527A (ja) 創傷被覆材及びその製造方法
Shera et al. Evaluation of protein/polysaccharide blend biopolymeric material for fabrication of drug eluting wound dressing

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004566875

Country of ref document: JP

122 Ep: pct application non-entry in european phase